Skip Nav Destination
Issues
1 September 2023
-
Cover Image
Cover Image
XMT-1660, a site-specific antibody-drug conjugate, shows potent anti-tumor activity in a syngeneic breast cancer model that does not express PD-L1 antigen (see graphical abstract). Read the full article on page 999. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
First Disclosures
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Dorin Toader; Shawn P. Fessler; Scott D. Collins; Patrick R. Conlon; Reddy Bollu; Kalli C. Catcott; Chen-Ni Chin; Anouk Dirksen; Bingfan Du; Jeremy R. Duvall; Stacy Higgins; Mariya V. Kozytska; Kamela Bellovoda; Chelsey Faircloth; David Lee; Fu Li; Liuliang Qin; Caitlin Routhier; Pamela Shaw; Cheri A. Stevenson; Jason Wang; Phonphimon Wongthida; Elena Ter-Ovanesyan; Elizabeth Ditty; Stephen P. Bradley; Ling Xu; Mao Yin; Alexandr V. Yurkovetskiy; Rebecca Mosher; Marc Damelin; Timothy B. Lowinger
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Weining Weng; Tao Meng; Junyi Pu; Linjie Ma; Yi Shen; Zhaohui Wang; Rong Pan; Mingqiao Wang; Caiwei Chen; Lijun Wang; Jianjian Zhang; Biao Zhou; Siyuan Shao; Yu Qian; Shuhui Liu; Wenhao Hu; Xun Meng
Review
Small Molecule Therapeutics
T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Vi Lam; Carly Roleder; Tingting Liu; Nur Bruss; Scott Best; Xiaoguang Wang; Tycel Phillips; Geoffrey Shouse; Allison J. Berger; Lapo Alinari; Lili Wang; Tanya Siddiqi; Nathan D. Pennock; Alexey V. Danilov
Large Molecule Therapeutics
S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Yoji Nagira; Morio Nagira; Ryohei Nagai; Wataru Nogami; Michinari Hirata; Azumi Ueyama; Tetsuya Yoshida; Mai Yoshikawa; Satomi Shinonome; Hiroshi Yoshida; Miya Haruna; Hiroto Miwa; Natsumi Chatani; Naganari Ohkura; Hisashi Wada; Hidekazu Tanaka
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
Sabine Zitzmann-Kolbe; Alexander Kristian; Dieter Zopf; Claudia Kamfenkel; Oliver Politz; Christine Ellingsen; Jochen Hilbig; Mark U. Juul; Jesper Fonslet; Carsten H. Nielsen; Christoph A. Schatz; Roger M. Bjerke; Alan S. Cuthbertson; Dominik Mumberg; Urs B. Hagemann
Targeting Drug Resistance
Models and Technologies
Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Stephen H. Chang; Ryan J. Ice; Michelle Chen; Maxim Sidorov; Rinette W.L. Woo; Aida Rodriguez-Brotons; Damon Jian; Han Kyul Kim; Angela Kim; David E. Stone; Ari Nazarian; Alyssia Oh; Gregory J. Tranah; Mehdi Nosrati; David de Semir; Altaf A. Dar; Pierre-Yves Desprez; Mohammed Kashani-Sabet; Liliana Soroceanu; Sean D. McAllister
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds